PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture

Journal of Nanobiotechnology

Volumn 8, Issue , 2010, Pages

  Lara, Humberto H ^a   Ixtepan Turrent, Liliana ^a   Garza Treviño, Elsa N ^a   Rodriguez Padilla, Cristina ^a  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL ACTIVITIES; BROAD SPECTRUM; CELL-FREE; CERVICAL TISSUES; CONCENTRATION OF; CYTOTOXIC; HIV-1 INFECTIONS; HOST CELLS; IN-VITRO; IN-VIVO; LONG LASTING; POLY VINYL PYRROLIDONE; PRE-TREATMENT; SILVER NANOPARTICLES; VIRUCIDAL ACTIVITY;

CELL CULTURE; GELS; NANOPARTICLES; VIRUSES;

SILVER;

POLYCARBOPHIL; POVIDONE; SILVER NANOPARTICLE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CELL FREE SYSTEM; DISEASE TRANSMISSION; DRUG COATING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; NONHUMAN; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77954403578     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-8-15     Document Type: Article

References (77)

1. Ray N. Maraviroc in the treatment of HIV infection. Drug Des Devel Ther 2009, 2:151-161. 2761192, 19920903.
2. Walker PR, Worobey M, Rambaut A, Holmes EC, Pybus OG. Epidemiology: Sexual transmission of HIV in Africa. Nature 2003, 422:679. 10.1038/422679a, 12700750.
3. Elias C, Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?. J Womens Health Gend Based Med 2001, 10:163-173. 10.1089/152460901300039502, 11268299.
4. Kalichman SC, Williams EA, Cherry C, Belcher L, Nachimson D. Sexual coercion, domestic violence, and negotiating condom use among low-income African American women. J Womens Health 1998, 7:371-378. 10.1089/jwh.1998.7.371, 9580917.
5. van der Straten A, King R, Grinstead O, Serufilira A, Allen S. Couple communication, sexual coercion and HIV risk reduction in Kigali, Rwanda. AIDS 1995, 9:935-944. 10.1097/00002030-199508000-00016, 7576330.
6. Balzarini J, Naesens L, Verbeken E, Laga M, Van DL, Parniak M, Van ML, Anne J, De CE. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent. AIDS 1998, 12:1129-1138. 10.1097/00002030-199810000-00004, 9677161.
7. McGowan I. Microbicides: a new frontier in HIV prevention. Biologicals 2006, 34:241-255. 10.1016/j.biologicals.2006.08.002, 17097303.
8. Fowler MG, Melnick SL, Mathieson BJ. Women and HIV. Epidemiology and global overview. Obstet Gynecol Clin North Am 1997, 24:705-729. 10.1016/S0889-8545(05)70340-5, 9430163.
9. Elias CJ, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996, 10(Suppl 3):S43-S51.
10. Brown H. Marvellous microbicides. Intravaginal gels could save millions of lives, but first someone has to prove that they work. Lancet 2004, 363:1042-1043. 10.1016/S0140-6736(04)15881-9, 15065555.
11. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008, 8:685-697. 10.1016/S1473-3099(08)70254-8, 18992405.
12. Pauwels R, De CE. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:211-221.
13. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003, 17:653-661. 10.1097/00002030-200303280-00002, 12646787.
14. Moscicki AB. Vaginal microbicides: where are we and where are we going?. J Infect Chemother 2008, 14:337-341. 10.1007/s10156-008-0630-3, 18936885.
15. Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav 2005, 9:121-131. 10.1007/s10461-005-1687-y, 15812619.
16. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des 2004, 10:315-336. 10.2174/1381612043386374, 14754390.
17. Weeks MR, Mosack KE, Abbott M, Sylla LN, Valdes B, Prince M. Microbicide acceptability among high-risk urban U.S. women: experiences and perceptions of sexually transmitted HIV prevention. Sex Transm Dis 2004, 31:682-690. 10.1097/01.olq.0000143113.04524.a5, 1567977, 15502677.
18. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000, 74:5577-5586. 10.1128/JVI.74.12.5577-5586.2000, 10823865.
19. Sadeghi-Nejad H, Wasserman M, Weidner W, Richardson D, Goldmeier D. Sexually transmitted diseases and sexual function. J Sex Med 2010, 7:389-413. 10.1111/j.1743-6109.2009.01622.x, 20092446.
20. Mcclelland RS, Wang CC, Mandaliya K, Overbaugh J, Reiner MT, Panteleeff DD, Lavreys L, Ndinya-Achola J, Bwayo JJ, Kreiss JK. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001, 15:105-110. 10.1097/00002030-200101050-00015, 11192850.
21. Coleman JS, Hitti J, Bukusi EA, Mwachari C, Muliro A, Nguti R, Gausman R, Jensen S, Patton D, Lockhart D, Coombs R, Cohen CR. Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS 2007, 21:755-759. 10.1097/QAD.0b013e328012b838, 17413697.
22. Weiler AM, Li Q, Duan L, Kaizu M, Weisgrau KL, Friedrich TC, Reynolds MR, Haase AT, Rakasz EG. Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J Virol 2008, 82:4154-4158. 10.1128/JVI.01947-07, 2292998, 18272571.
23. Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P. Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 2000, 6:475-479. 10.1038/74743, 10742159.
24. Zussman A, Lara L, Lara HH, Bentwich Z, Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003, 17:653-661. 10.1097/00002030-200303280-00002, 12646787.
25. Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol 2005, 153:521-525. 10.1111/j.1365-2133.2005.06490.x, 16120136.
26. Tanweer F, Hanif J. Re: Silver nitrate cauterisation, does concentration matter?. Clin Otolaryngol 2008, 33:503-504. 10.1111/j.1749-4486.2008.01803.x, 18983401.
27. Link TR, Conley SF, Flanary V, Kerschner JE. Bilateral epistaxis in children: efficacy of bilateral septal cauterization with silver nitrate. Int J Pediatr Otorhinolaryngol 2006, 70:1439-1442. 10.1016/j.ijporl.2006.03.003, 16621035.
28. Lowe DG, Levison DA, Crocker PR, Shepherd JH. Silver deposition in the cervix after application of silver nitrate as a cauterising agent. J Clin Pathol 1988, 41:871-874. 10.1136/jcp.41.8.871, 1141618, 3049682.
29. Hoyme UB. Clinical Significance of Crede's Prophylaxis in Germany at Present. Infect Dis Obstet Gynecol 1993, 1:32-36. 10.1155/S1064744993000080, 2364679, 18476203.
30. Lok CN, Ho CM, Chen R, He QY, Yu WY, Sun H, Tam PK, Chiu JF. Che CM: Silver nanoparticles: partial oxidation and antibacterial activities. J Biol Inorg Chem 2007, 12:527-534. 10.1007/s00775-007-0208-z, 17353996.
31. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, Kim SH, Park YK, Park YH, Hwang CY, Kim YK, Lee YS, Jeong DH, Cho MH. Antimicrobial effects of silver nanoparticles. Nanomedicine 2007, 3:95-101.
32. Morones JR, Elechiguerra JL, Camacho A, Holt K, Kouri JB, Tapia J, Yacaman MJ. The bactericidal effect of silver nanoparticles. Nanotechnology 2005, 16:2346-2353.
33. Shahverdi AR, Fakhimi A, Shahverdi HR, Minaian S. Synthesis and effect of silver nanoparticles on the antibacterial activity of different antibiotics against Staphylococcus aureus and Escherichia coli. Nanomedicine 2007, 3:168-171.
34. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 2004, 275:177-182. 10.1016/j.jcis.2004.02.012, 15158396.
35. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Bactericidal effect of silver nanoparticles against multidrug-resistant bacteria. World Journal of Microbiology and Biotechnology 2009, 2872801, 20495624.
36. Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnology 2010, 2818642, 20145735.
37. Tian J, Wong KK, Ho CM, Lok CN, Yu WY, Che CM, Chiu JF, Tam PK. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2007, 2:129-136. 10.1002/cmdc.200600171, 17075952.
38. Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns 2004, 30(Suppl 1):S1-S9. 10.1016/S0305-4179(04)90000-9, 15327800.
39. Neurath AR, Strick N, Li YY, Debnath AK. Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001, 1:17. 10.1186/1471-2334-1-17, 57811, 11602021.
40. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005, 3:6. 10.1186/1477-3155-3-6, 15987516.
41. Ayala-Nuñez NV, Lara HH, Ixtepan-Turrent L, Rodriguez-Padilla C. Silver Nanoparticles Toxicity and Bactericidal Effect Against Methicillin-Resistant Staphylococcus aureus: Nanoscale Does Matter. J Nanobiotechnology 2009,
42. Borkow G, Lara HH, Covington CY, Nyamathi A, Gabbay J. Deactivation of human immunodeficiency virus type 1 in medium by copper oxide-containing filters. Antimicrob Agents Chemother 2008, 52:518-525. 10.1128/AAC.00899-07, 2224774, 18070974.
43. Cummins JE, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA, Paxton L, Dezzutti CS. Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 2007, 51:1770-1779. 10.1128/AAC.01129-06, 1855576, 17353237.
44. Terrazas-Aranda K, Van HY, Hazuda D, Lewi P, Costi R, Di SR, Cara A, Vanham G. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrob Agents Chemother 2008, 52:2544-2554. 10.1128/AAC.01627-07, 2443891, 18474579.
45. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008, 59:455-471. 10.1146/annurev.med.59.061206.112737, 17892435.
46. Sexton A, Harman S, Shattock RJ, Ma JK. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 2009, 23:3590-3600. 10.1096/fj.09-131995, 19470798.
47. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 2008, 8:685-697. 10.1016/S1473-3099(08)70254-8, 2627483, 18992405.
48. Bhol KC, Schechter PJ. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol 2005, 152:1235-1242. 10.1111/j.1365-2133.2005.06575.x, 15948987.
49. Sibbald RG, Contreras-Ruiz J, Coutts P, Fierheller M, Rothman A, Woo K. Bacteriology, inflammation, and healing a study of nanocrystalline silver dressings in chronic venous leg ulcers. Adv Skin Wound Care 2007, 20:549-558. 10.1097/01.ASW.0000294757.05049.85, 17906429.
50. Arora S, Jain J, Rajwade JM, Paknikar KM. Cellular responses induced by silver nanoparticles: In vitro studies. Toxicol Lett 2008, 179:93-100. 10.1016/j.toxlet.2008.04.009, 18508209.
51. Larese FF, D'Agostin F, Crosera M, Adami G, Renzi N, Bovenzi M, Maina G. Human skin penetration of silver nanoparticles through intact and damaged skin. Toxicology 2009, 255:33-37. 10.1016/j.tox.2008.09.025, 18973786.
52. Larese FF, D'Agostin F, Crosera M, Adami G, Renzi N, Bovenzi M, Maina G. Human skin penetration of silver nanoparticles through intact and damaged skin. Toxicology 2009, 255:33-37. 10.1016/j.tox.2008.09.025, 18973786.
53. Zhang LW, Monteiro-Riviere NA. Assessment of quantum dot penetration into intact, tape-stripped, abraded and flexed rat skin. Skin Pharmacol Physiol 2008, 21:166-180. 10.1159/000131080, 18523414.
54. Tian J, Wong KK, Ho CM, Lok CN, Yu WY, Che CM, Chiu JF, Tam PK. Topical delivery of silver nanoparticles promotes wound healing. ChemMedChem 2007, 2:129-136. 10.1002/cmdc.200600171, 17075952.
55. Shattock RJ, Griffin GE, Gorodeski GI. In vitro models of mucosal HIV transmission. Nat Med 2000, 6:607-608. 10.1038/76138, 10835650.
56. Gupta P, Collins K, Patterson B, Naus G, Landers D. Reply to 'In vitro models of mucosal HIV transmission'. Nat Med 2000, 6:607-608. 10.1038/76141, 10835651.
57. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000, 74:5577-5586. 10.1128/JVI.74.12.5577-5586.2000, 112045, 10823865.
58. Greulich C, Kittler S, Epple M, Muhr G, Koller M. Studies on the biocompatibility and the interaction of silver nanoparticles with human mesenchymal stem cells (hMSCs). Langenbecks Arch Surg 2009, 394:495-502. 10.1007/s00423-009-0472-1, 19280220.
59. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, Goujard C, Debord T, Montagnier L. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996, 156:3509-3520.
60. Poon VK, Burd A. In vitro cytotoxity of silver: implication for clinical wound care. Burns 2004, 30:140-147. 10.1016/j.burns.2003.09.030, 15019121.
61. Wright JB, Lam K, Buret AG, Olson ME, Burrell RE. Early healing events in a porcine model of contaminated wounds: effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen 2002, 10:141-151. 10.1046/j.1524-475X.2002.10308.x, 12100375.
62. Benkop-Schnurch A, Hornof M. Intravaginal drug delivery systems:Design, Challenges and Solutions. Adv Drug Deliv Rev 2003, 4:241-254.
63. Mauck C, Rosenberg Z, Van DL. Recommendations for the clinical development of topical microbicides: an update. AIDS 2001, 15:857-868. 10.1097/00002030-200105040-00006, 11399958.
64. Lynch G, Low L, Li S, Sloane A, Adams S, Parish C, Kemp B, Cunningham AL. Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J Leukoc Biol 1994, 56:266-272.
65. Harrison PF, Rosenberg Z, Bowcut J. Topical microbicides for disease prevention: status and challenges. Clin Infect Dis 2003, 36:1290-1294. 10.1086/374834, 12746775.
66. Dezzutti CS, James VN, Ramos A, Sullivan ST, Siddig A, Bush TJ, Grohskopf LA, Paxton L, Subbarao S, Hart CE. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 2004, 48:3834-3844. 10.1128/AAC.48.10.3834-3844.2004, 521884, 15388443.
67. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000, 74:1948-1960. 10.1128/JVI.74.4.1948-1960.2000, 111673, 10644368.
68. Moscicki AB. Vaginal microbicides: where are we and where are we going?. J Infect Chemother 2008, 14:337-341. 10.1007/s10156-008-0630-3, 18936885.
69. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005, 3:6. 10.1186/1477-3155-3-6, 15987516.
70. Rohan LC, Sassi AB. Vaginal drug delivery systems for HIV prevention. AAPS J 2009, 11:78-87. 10.1208/s12248-009-9082-7, 2664883, 19194802.
71. Elechiguerra JL, Burt JL, Morones JR, Camacho-Bragado A, Gao X, Lara HH, Yacaman MJ. Interaction of silver nanoparticles with HIV-1. J Nanobiotechnology 2005, 3:6. 10.1186/1477-3155-3-6, 1190212, 15987516.
72. Ndesendo VM, Pillay V, Choonara YE, Buchmann E, Bayever DN, Meyer LC. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 2008, 9:505-520. 10.1208/s12249-008-9073-5, 18431651.
73. Bhol KC, Schechter PJ. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol 2005, 152:1235-1242. 10.1111/j.1365-2133.2005.06575.x, 15948987.
74. Balzarini J, Brouwer WG, Dao DC, Osika EM, De CE. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob Agents Chemother 1996, 40:1454-1466. 163349, 8726019.
75. Borkow G, Vijayabaskar V, Lara HH, Kalinkovich A, Lapidot A. Structure-activity relationship of neomycin, paromomycin, and neamine-arginine conjugates, targeting HIV-1 gp120-CXCR4 binding step. Antiviral Res 2003, 60:181-192. 10.1016/S0166-3542(03)00156-6, 14638394.
76. Borkow G, Lara HH, Lapidot A. Mutations in gp41 and gp120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate. Biochem Biophys Res Commun 2003, 312:1047-1052. 10.1016/j.bbrc.2003.11.011, 14651977.
77. Montefiori DC, Robinson WE, Schuffman SS, Mitchell WM. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol 1988, 26:231-235. 266258, 3422647.